湖北亨迪藥業(yè)股份有限公司(股票代碼：301211.SZ) 2002年來開始承接CDMO業(yè)務(wù)，是中國領(lǐng)先的CDMO服務(wù)企業(yè)和特色原料藥生產(chǎn)企業(yè)。20年來向全球跨國藥企和新藥研創(chuàng)公司提供委托研發(fā)和委托生產(chǎn)服務(wù)。能夠為全球客戶提供從新藥臨床前藥學(xué)研究、臨床及各階段原料藥工藝研發(fā)和生產(chǎn)、到商業(yè)化生產(chǎn)的一站式服務(wù)，其中包括多個中美雙報項目。總反應(yīng)能力約1000立方，涵蓋多個OEB4-5高活性GMP生產(chǎn)線，反應(yīng)釜體積5L~5000L，能承接從克、公斤、噸、百噸、千噸等不同規(guī)模的小分子原料藥及中間體的合同研發(fā)與生產(chǎn)業(yè)務(wù)。

Hubei Heilen Pharmaceutical Co., Ltd. (stock code: 301211. SZ) has been undertaking CDMO business since 2002 and is a leading enterprise of CDMO service and generic API production in China. During past 20 years, we have provided CDMO/CMO services to global pharmaceutical companies and new drug research and development companies. We are able to provide one-stop services for global clients, including preclinical pharmaceutical research for new drugs, research and development and production of API at clinical and various stages, and commercial production, including multiple Sino US dual registration projects. The total reaction capacity is about 1000M3, covering multiple OEB4-5 Highly Potent API GMP production lines, with a reactor volume of 5L~5000L. It can undertake CDMO/CMO business of small molecule APIs and intermediates of different scales from grams/kilos to thousands of tons.